The Journal of Clinical Psychiatry
April 5, 2023
Albert Yeung, Guy Sapirstein, Laura D Crain et al.
Although consensus in the field is lacking, the most common definition for treatment-resistant depression (TRD) requires a minimum of 2 prior treatment failures with confirmed adequate dose and duration. This article presents a clinical example of TRD in a patient with a long history of depression and inadequate response to treatment. The prominent feature is the patient's persistent...
Journal of Affective Disorders
April 1, 2023
Olivier Payette, Paul Lespérance, V. D. Jodoin et al.
7 citations
BACKGROUND For individuals with treatment-resistant depression (TRD), transcranial magnetic stimulation (TMS) has become a well-established approach. In the past decade, intravenous (IV) racemic ketamine has also emerged as a potential treatment for TRD. Currently, little data is available on the clinical effects of IV racemic ketamine in TRD patients who experienced TMS-failure. METHODS...
Pharmaceuticals
April 1, 2023
Aleksander Kwaśny, A. Włodarczyk, Damian Ogonowski et al.
27 citations
Background: Depression is a debilitating disease with a high socioeconomic burden. Regular antidepressants usually require several weeks to ameliorate symptoms; however, numerous patients do not achieve remission. What is more, sleep disturbances are one of the most common residual symptoms. Ketamine is a novel antidepressant with rapid onset of action with a proven antisuicidal effect. Little...
Journal of Affective Disorders
April 1, 2023
Artemis Zavaliangos-Petropulu, Shawn M. Mcclintock, Jacqueline Khalil et al.
16 citations
INTRODUCTION Ketamine treatment prompts a rapid antidepressant response in treatment-resistant depression (TRD). We performed an exploratory investigation of how ketamine treatment in TRD affects different cognitive domains and relates to antidepressant response. METHODS Patients with TRD (N = 66; 30 M/35F; age = 39.5 ± 11.1 years) received four ketamine infusions (0.5 mg/kg). Neurocognitive...
Psychopharmacology
April 1, 2023
David S. Mathai, Sandeep M. Nayak, David B. Yaden et al.
36 citations
The relationship between subjective drug experience and antidepressant outcomes for ketamine derivatives is poorly understood but of high clinical relevance. Esketamine is the patented (S)-enantiomer of ketamine and has regulatory approval for psychiatric applications. We examined the relationship between acute dissociation, as measured by the Clinician-Administered Dissociative States Scale...
Expert Review of Clinical Pharmacology
April 1, 2023
Jeffrey M. Witkin, Lalit K Golani, Jodi L Smith
18 citations
Deficiencies in standard of care antidepressants are driving novel drug discovery. A new age of antidepressant medications has emerged with the introduction of rapid-acting antidepressants with efficacy in treatment-resistant patients. The newly approved medicines and those in clinical development for major depressive disorder (MDD) are documented in this scoping review of newly approved and...
Neurochemical Research
April 1, 2023
Jared VanderZwaag, Torin Halvorson, Kira Dolhan et al.
25 citations
There is much excitement surrounding recent research of promising, mechanistically novel psychotherapeutics - psychedelic, anesthetic, and dissociative agents - as they have demonstrated surprising efficacy in treating central nervous system (CNS) disorders, such as mood disorders and addiction. However, the mechanisms by which these drugs provide such profound psychological benefits are still...
Neuropsychiatric Disease and Treatment
March 31, 2023
Xu Chen, Xuan Hou, Daisy Bai et al.
Purpose: This Phase 3, multicenter study (NCT03434041) was conducted in primarily Chinese patients with treatment-resistant depression (TRD) to support the registration of esketamine nasal spray in China. Patients and methods: This randomized, double-blind, active-controlled study was conducted in China and the United States (US) in patients with TRD (single or recurrent episode). Eligible...
Pakistan Armed Forces Medical Journal
March 30, 2023
Asif Azeem Bajwa, Sohail Ali, Sikandar Ali Khan et al.
1 citation
Objective: To evaluate and compare the efficacy of Electroconvulsive therapy (ECT) and Ketamine infusions in hospitalized patients suffering from major depressive disorder (MDD). Study Design: Comparative cross-sectional study. Place and duration of study: Armed Forces Institute of Mental Health, Rawalpindi Pakistan, from Feb to Apr 2021. Methodology: Forty in-patients diagnosed as having MDD...
Bipolar Disorders
March 28, 2023
Balwinder Singh
Ketamine is a novel drug used for treatment- resistant depression. The initial randomized controlled trials (RCTs) established intravenous (IV) ketamine's rapid antidepressant effects for refrac-tory major depression, leading to its widespread use. However, the data for ketamine's efficacy in treatment- resistant bipolar depression (TRBD) remain minimal. There are 3 single infusion RCTs ( n =...